LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 96 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $18,600 | +28.2% | 12,400 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $14,508 | +3.6% | 12,400 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $14,000 | -30.0% | 12,400 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $20,000 | +5.3% | 12,400 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $19,000 | -36.7% | 12,400 | 0.0% | 0.00% | -50.0% |
Q4 2021 | $30,000 | -36.2% | 12,400 | -32.6% | 0.00% | -33.3% |
Q3 2021 | $47,000 | -29.9% | 18,400 | -21.2% | 0.00% | -40.0% |
Q2 2021 | $67,000 | +45.7% | 23,360 | +18.8% | 0.01% | +25.0% |
Q1 2021 | $46,000 | +70.4% | 19,670 | +24.9% | 0.00% | +100.0% |
Q4 2020 | $27,000 | +92.9% | 15,750 | +6.8% | 0.00% | +100.0% |
Q3 2020 | $14,000 | 0.0% | 14,750 | -8.7% | 0.00% | 0.0% |
Q2 2020 | $14,000 | -6.7% | 16,150 | -19.9% | 0.00% | -50.0% |
Q1 2020 | $15,000 | -16.7% | 20,150 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $18,000 | -47.1% | 20,150 | -42.7% | 0.00% | -50.0% |
Q3 2019 | $34,000 | – | 35,150 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,005,379 | $28,160,000 | 3.29% |
Defender Capital, LLC. | 4,416,590 | $3,657,000 | 2.67% |
Prescott General Partners LLC | 1,851,851 | $1,534,000 | 0.13% |
Laidlaw Wealth Management LLC | 107,379 | $89,000 | 0.06% |
Northeast Financial Consultants Inc | 523,756 | $434,000 | 0.05% |
Beirne Wealth Consulting Services, LLC | 45,000 | $37,000 | 0.04% |
DAFNA Capital Management LLC | 95,000 | $79,000 | 0.03% |
Summit X, LLC | 30,700 | $25,000 | 0.01% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 529,039 | $438,000 | 0.01% |
Keudell/Morrison Wealth Management | 10,105 | $8,000 | 0.01% |